MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL

Bruce E. Sands  1     Severine Vermeire  2     Marla C. Dubinsky  1     Brian G. Feagan  3, 4     Remo Panaccione  5     Vipul Jairath  3     Andres Yarur  6     Michael Chiorean  7     Julian Panés  8     Martina Goetsch  9     Christopher J. Rabbat  10     Pooja Shah  11     Joseph Wu  12     Subrata Ghosh  13    
1 Icahn School of Medicine at Mount Sinai, New York, United States
2 University Hospitals Leuven, Leuven, Belgium
3 Western University, London, Canada
4 Alimentiv Inc, London, Canada
5 University of Calgary, Calgary, Canada
6 Cedars-Sinai Medical Center, Los Angeles, United States
7 Swedish Medical Center, Seattle, United States
8 Formerly Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
9 Pfizer AG, Zürich, Switzerland
10 Pfizer Inc, New York, United States
11 Pfizer Inc, Collegeville, United States
12 Pfizer Inc, Groton, United States
13 APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing